301207 华兰疫苗
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-0.0823.1223.34814.62612.514
总资产报酬率 ROA (%)-0.0682.5462.64911.4128.960
投入资产回报率 ROIC (%)-0.0823.0343.18113.86811.346

边际利润分析
销售毛利率 (%)62.65377.80181.15388.08988.089
营业利润率 (%)-6.02815.78219.05141.90432.462
息税前利润/营业总收入 (%)-6.58315.46918.39741.56431.989
净利润/营业总收入 (%)-1.47915.21218.22235.67728.463

收益指标分析
经营活动净收益/利润总额(%)599.33196.38277.61999.640117.066
价值变动净收益/利润总额(%)-307.77747.67846.78410.94212.290
营业外收支净额/利润总额(%)1.052-1.060-0.145-0.315-0.535

偿债能力分析
流动比率 (X)4.6353.9243.3993.1012.728
速动比率 (X)4.2923.7643.2562.9982.619
资产负债率 (%)17.63816.65620.07321.66622.316
带息债务/全部投入资本 (%)0.341-0.1904.4434.1244.853
股东权益/带息债务 (%)29,074.344-52,467.2202,134.3452,307.4211,945.534
股东权益/负债合计 (%)466.963500.388398.192361.563348.118
利息保障倍数 (X)13.407-105.200-29.372-199.512-106.640

营运能力分析
应收账款周转天数 (天)1,013.777416.940547.106282.792318.997
存货周转天数 (天)662.464261.658323.749213.562227.277